Neurogene Inc
NASDAQ:NGNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Neurogene Inc
NASDAQ:NGNE
|
US |
|
Pidilite Industries Ltd
BSE:500331
|
IN |
|
Avalon Advanced Materials Inc
TSX:AVL
|
CA |
|
Strike Energy Ltd
ASX:STX
|
AU |
|
O
|
Opticept Technologies AB
STO:OPTI
|
SE |
|
N
|
NovaGold Resources Inc
AMEX:NG
|
US |
|
I
|
Interra Resources Ltd
SGX:5GI
|
SG |
|
Ondas Holdings Inc
NASDAQ:ONDS
|
US |
|
Garudafood Putra Putri Jaya Tbk PT
IDX:GOOD
|
ID |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
US |
|
F
|
Fitell Corp
NASDAQ:FTEL
|
AU |
|
EJF Investments Ltd
LSE:EJFI
|
JE |
|
Hunting PLC
LSE:HTG
|
UK |
|
H
|
Himalaya Shipping Ltd
OSE:HSHIP
|
BM |
|
F
|
Future Enterprises Ltd
NSE:FELDVR
|
IN |
|
Koninklijke KPN NV
AEX:KPN
|
NL |
|
Kothari Fermentation and Biochem Ltd
BSE:507474
|
IN |
|
Jewett-Cameron Trading Company Ltd
NASDAQ:JCTCF
|
US |
|
T
|
Taiwan Chelic Co Ltd
TWSE:4555
|
TW |
Neurogene Inc
Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.
Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.
